Table 1.
Clinicopathological characteristics group A.
| Variable | n = 196 | SARIFA-Positive (n = 31) | SARIFA-Negative (n = 165) | p-Value/p-Value Adjusted * | ||||
|---|---|---|---|---|---|---|---|---|
| Median Age [years] | 71 (64–79) | 70 (64–74) | 72(64–79) | 0.129/1.0 | ||||
| Median Follow-up (95% CI) [years] | 6.4 (5.6–7.1) | 6.0 (5.5–6.6) | 7.0 (5.0–9.1) | 0.581/1.0 | ||||
| Median Lymph Node Harvest (n) | 20 (13–30) | 20 (15–40) | 19 (13–29) | 0.254/1.0 | ||||
| Positive Lymph Nodes (n) | 0 (0–1) | 1 (0–4) | 0 (0–1) | 0.002/0.036 | ||||
| Sex | 0.843/1.0 | |||||||
| female | 83 | 42% | 14 | 45% | 69 | 42% | ||
| male | 113 | 58% | 17 | 55% | 96 | 58% | ||
| T status | 0.229/1.0 | |||||||
| pT3 | 172 | 88% | 25 | 81% | 147 | 89% | ||
| pT4 | 24 | 12% | 6 | 19% | 18 | 11% | ||
| N status | 0.009/0.144 | |||||||
| negative | 119 | 61% | 12 | 39% | 107 | 65% | ||
| positive | 77 | 39% | 19 | 61% | 58 | 35% | ||
| Grading | 0.020/0.280 | |||||||
| low grade | 137 | 70% | 16 | 52% | 121 | 73% | ||
| high grade | 59 | 30% | 15 | 48% | 44 | 27% | ||
| Vascular Invasion | 0.098/1.0 | |||||||
| negative | 176 | 90% | 25 | 81% | 151 | 91% | ||
| positive | 20 | 10% | 6 | 19% | 14 | 9% | ||
| Lymphatic Vessel Invasion | 0.602/1.0 | |||||||
| negative | 164 | 84% | 25 | 81% | 139 | 84% | ||
| positive | 32 | 16% | 6 | 19% | 26 | 16% | ||
| Tumor Budding | 0.004/0.068 | |||||||
| Bd1 | 161 | 82% | 20 | 65% | 141 | 86% | ||
| Bd2 | 23 | 12% | 6 | 19% | 17 | 10% | ||
| Bd3 | 12 | 6% | 5 | 16% | 7 | 4% | ||
| Location | 0.841/1.0 | |||||||
| right sided | 120 | 61% | 20 | 65% | 100 | 61% | ||
| left sided | 76 | 39% | 11 | 36% | 65 | 39% | ||
| MSS | 0.773/1.0 | |||||||
| stable | 172 | 88% | 28 | 90% | 144 | 87% | ||
| instable | 24 | 12% | 3 | 10% | 21 | 13% | ||
| Adjuvant Chemotherapy | 0.123/1.0 | |||||||
| no | 107 | 55% | 13 | 42% | 94 | 57% | ||
| yes | 89 | 45% | 18 | 58% | 71 | 43% | ||
| Distant Metastasis | 0.624/1.0 | |||||||
| no | 158 | 81% | 24 | 77% | 134 | 81% | ||
| yes | 38 | 19% | 7 | 23% | 31 | 19% | ||
| Death | 0.113/1.0 | |||||||
| no | 115 | 59% | 14 | 45% | 101 | 61% | ||
| death | 81 | 41% | 17 | 55% | 64 | 39% | ||
| Colon-Cancer-Specific Survival | 0.014/0.210 | |||||||
| no | 173 | 88% | 23 | 74% | 150 | 91% | ||
| death | 23 | 12% | 8 | 26% | 15 | 9% | ||
| Five Year Survival (n = 152) | 0.272/1.0 | |||||||
| survived | 92 | 60% | 13 | 50% | 79 | 63% | ||
| death | 60 | 40% | 13 | 50% | 47 | 37% | ||
Legend: 95% CI, 95% confidence interval; p-values are shown for difference between SARIFA (Stroma AReactive Invasion Front Areas) positive and SARIFA-negative tumors; Abbreviations: MSS: microsatellite stability status; * adjusted using Bonferroni Holm method [37].